Danaher Corp. closed 30.42% short of its 52-week high of $281.70, which the company achieved on August 1st.

Danaher Corporation DHR has been benefiting from strength in its bioprocessing business, driven by an increase in demand for consumables from large pharmaceutical customers in North America, Europe ...

Shares of Danaher Corp. slipped 5.54% to $186.81 Wednesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index falling 1.61% to 5,844.61 and Dow Jones ...

Danaher Corporation (NYSE:DHR) and AstraZeneca PLC (NASDAQ:AZN) have announced a major partnership to accelerate the ...

Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An ...

Danaher Corporation (NYSE:DHR) shareholders are probably feeling a little disappointed, since its shares fell 9.2% to US$223 in the week after its latest annual results. It looks like the results ...

Danaher Corporation, a key player in Life Sciences, Biotechnology, and Diagnostics, has shown mixed financial performance with recent declines in revenue and net earnings. Despite recent struggles ...

Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments ...

Sept 14 (Reuters) - Danaher Corp (DHR.N), opens new tab said on Wednesday it would separate its environmental & applied solutions (EAS) segment to pivot growth towards the medical technology firm ...

Shares of General Electric Co. surged Monday after a deal to sell its biopharma business for $21.4 billion in cash to Danaher Corp, but remained on track to extend their longest streak below the ...

Danaher Corporation incorporates science and technology and has a market cap of $150B. The company has mixed financials, with its gross profit margin being its strongest and most consistent.